Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,458 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Cardiovascular safety of vibegron, a new β3-adrenoceptor agonist, in older patients with overactive bladder: Post-hoc analysis of a randomized, placebo-controlled, double-blind comparative phase 3 study.
Yoshida M, Takeda M, Gotoh M, Yokoyama O, Kakizaki H, Takahashi S, Masumori N, Nagai S, Minemura K. Yoshida M, et al. Among authors: nagai s. Neurourol Urodyn. 2021 Aug;40(6):1651-1660. doi: 10.1002/nau.24732. Epub 2021 Jun 17. Neurourol Urodyn. 2021. PMID: 34139038 Free PMC article. Clinical Trial.
Efficacy of novel β3 -adrenoreceptor agonist vibegron on nocturia in patients with overactive bladder: A post-hoc analysis of a randomized, double-blind, placebo-controlled phase 3 study.
Yoshida M, Takeda M, Gotoh M, Yokoyama O, Kakizaki H, Takahashi S, Masumori N, Nagai S, Hashimoto K, Minemura K. Yoshida M, et al. Among authors: nagai s. Int J Urol. 2019 Mar;26(3):369-375. doi: 10.1111/iju.13877. Epub 2018 Dec 17. Int J Urol. 2019. PMID: 30557916 Free PMC article. Clinical Trial.
Efficacy of vibegron, a novel β3-adrenoreceptor agonist, on severe urgency urinary incontinence related to overactive bladder: post hoc analysis of a randomized, placebo-controlled, double-blind, comparative phase 3 study.
Yoshida M, Takeda M, Gotoh M, Yokoyama O, Kakizaki H, Takahashi S, Masumori N, Nagai S, Minemura K. Yoshida M, et al. Among authors: nagai s. BJU Int. 2020 May;125(5):709-717. doi: 10.1111/bju.15020. Epub 2020 Feb 23. BJU Int. 2020. PMID: 31991511 Free PMC article. Clinical Trial.
Efficacy of imeglimin treatment versus metformin dose escalation on glycemic control in subjects with type 2 diabetes treated with a dipeptidyl peptidase-4 inhibitor plus low-dose metformin: A multicenter, prospective, randomized, open-label, parallel-group comparison study (MEGMI study).
Takahashi A, Nomoto H, Yokoyama H, Yokozeki K, Furusawa S, Oe Y, Kameda R, Kawata S, Miyoshi A, Nagai S, Miya A, Kameda H, Nakamura A, Atsumi T; MEGMI study group. Takahashi A, et al. Among authors: nagai s. Diabetes Obes Metab. 2024 Dec 26. doi: 10.1111/dom.16150. Online ahead of print. Diabetes Obes Metab. 2024. PMID: 39726204
1,458 results